Bioreactors Market by Type of Bioreactor (Stainless Steel, Single-use, Glass), Type of Bioprocesses (Batch and Fed-batch, and Continuous), Type of Biologic, Type of Cell Culture, Scale of Bioreactor (Micro-scale Bioreactors, Lab-scale Bioreactors, Large-scale Bioreactors and Very Large-scale Bioreactors), and Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)- Industry Trends and Forecast, 2026-2035
Bioreactors Market Outlook: USD 44.2 Billion by 2035 at a 9.4% CAGR
The bioreactors market, valued at USD 17.7 billion in 2025, is projected to reach USD 19.6 billion in 2026 and USD 44.2 billion by 2035, representing a CAGR of 9.4% during the forecast period 2026 to 2035. Growth is being supported by the increasing demand for biopharmaceuticals / biologics (including monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies), expansion of biomanufacturing capacity, and rising adoption of single-use bioreactors and advanced / continuous bioprocessing technologies.
See What's in the Full Report – Request Your Complimentary Insights!
Market Report: Key Takeaways
- Stainless steel bioreactors capture the largest market share, supported by their durability, cleanability, sterilization compatibility and suitability for large-scale, multi-batch commercial manufacturing.
- Monoclonal antibodies hold the dominant position by type of biologic, supported by sustained therapeutic demand and continued expansion of commercial antibody-manufacturing capacity.
- Batch and fed-batch bioprocesses account for nearly 85% of the market by type of bioprocess, reflecting their broad adoption, process reliability and scalability across biologics manufacturing.
- Mammalian cell cultures capture the largest share by type of cell culture, driven by their extensive use in commercial production of monoclonal antibodies and other therapeutically relevant proteins.
- Very large-scale bioreactors account for more than 80% of the market by bioreactor scale, supported by high-volume commercial production and economies of scale.
- Europe holds approximately 35% of the market, supported by established biopharmaceutical manufacturing infrastructure, public and private investment and adoption of advanced bioprocessing technologies.
Key Market Statistics
- Market Size, 2026: USD 19.6 Billion
- Market Size, 2035: USD 44.2 Billion
- CAGR (2026-2035): 9.4%
- Largest Region: Europe
- Fastest Growing Region: Asia-Pacific
Scope, Methodology and Industry Experts Interviews
This report focuses on bioreactors used for controlled biological processes, including mammalian cell culture, microbial fermentation and other aseptic biomanufacturing applications. The market analysis covers stainless steel, single-use and glass systems across batch, fed-batch and continuous processing, multiple biologic types, cell culture systems, scales of operation and geographical regions.
The findings presented in this study were developed through a structured methodology combining secondary research, proprietary databases, company disclosures, regulatory filings, academic and industry publications and primary research. The analysis triangulates evidence across bioreactor demand, installed manufacturing capacity, technology adoption, production scale, single-use and stainless steel system usage, manufacturing investment, supply-chain dynamics, regulatory requirements and regional market conditions to validate market assumptions and forecast estimates.
The market report includes transcripts of the following third-party discussions:
- Co-founder, Small Organization, Spain
- Vice President of Global Supply Chain, Very Large Organization, US
- Director of Manufacturing, Small Organization, Canada
- Associate Director, Extractable/Leachable and GC/MS Services, Very Large Organization, US
- Senior Global Product Manager, Very Large Organization, US
- Senior Product Manager, Very Large Organization, US
- Business Development Manager, Very Large Organization, Switzerland
- Manager, Analytical Science, Very Large Organization, US
- Manager of External Collaborations for Separations Technology, Very Large Organization, Germany
- Application Specialist, Large Organization, Germany
What is the Bioreactors Market?
Bioreactors are controlled vessels or processing systems used to cultivate mammalian, microbial, insect and other cell cultures under defined conditions for biopharmaceutical manufacturing. They regulate parameters such as temperature, pH, dissolved oxygen, agitation, gas flow and nutrient supply to support reproducible cell growth and product formation. In biopharmaceutical applications, bioreactors are used to manufacture monoclonal antibodies, recombinant proteins produced through recombinant-DNA expression systems, vaccines, biosimilars, cell and gene therapy products and other biologics. Common designs include stirred-tank, wave and airlift systems, while fabrication platforms range from stainless steel and glass to single-use polymer assemblies.
Bioreactor selection depends on cell type, production volume, oxygen-transfer requirements, shear sensitivity, sterility needs, scale and process strategy. Stainless steel systems remain important for durable, high-volume commercial production, while single-use bioreactors can reduce cleaning requirements, turnaround time and initial infrastructure needs for multiproduct or flexible facilities. However, single-use systems introduce consumables and supply-chain considerations, whereas stainless steel platforms require greater capital investment, cleaning validation and maintenance. Across both formats, automation, sensors, real-time monitoring and modular process-control technologies are improving accuracy, process consistency and scale-up efficiency.
What is Driving Growth in the Bioreactors Market Through 2035?
- Expansion of Biologics and Advanced Therapy Manufacturing: Increasing commercialization of monoclonal antibodies, recombinant proteins, vaccines, biosimilars, cell therapies and gene therapies is increasing demand for scalable and flexible upstream manufacturing systems. Growth in genetically engineered mammalian and microbial production platforms is also supporting demand for bioreactors across commercial biologics and industrial fermentation workflows.
- Shift Toward Flexible Manufacturing Models: Multiproduct facilities, faster product changeovers and pressure to reduce facility downtime are supporting adoption of modular and single-use bioreactor platforms. These systems can improve operational flexibility and enable manufacturers to scale production more rapidly as pipeline requirements change.
- Growing Contract Manufacturing Activities: Contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) are expanding flexible bioreactor capacity to support diverse client programs, production scales and biologic modalities. Outsourcing demand is therefore increasing investment in bioreactor infrastructure, technical support and scalable upstream manufacturing capacity.
Recent Developments in the Bioreactors Market
- In May 2026, ABEC announced an expansion of its Process Sciences group to strengthen support for biopharmaceutical manufacturers seeking to accelerate development, reduce process risk and improve productivity across the bioprocess lifecycle.
- In April 2026, Distek entered into an exclusive manufacturer's representative agreement with Optimal Biotech Group to expand access to its BIOne benchtop bioreactor solutions across California, Oregon and Washington.
- In December 2025, PBS Biotech launched MiniPRO, a multi-parallel Vertical-Wheel bioreactor platform designed to support high-throughput cell therapy process development.
Your Business is Unique – Why Shouldn't Your Report Be?
Bioreactors Market Trends
- Partnerships and Collaborations: Bioreactor manufacturers are increasingly collaborating with biopharmaceutical companies, research organizations, technology providers and contract manufacturers to co-develop bioprocessing platforms, improve workflow integration and accelerate upstream process innovation. For instance, in November 2025, n!Biomachines entered into a partnership with the Weizmann Institute of Science to accelerate bioreactor technology development.
- Recent Expansions: Manufacturers are expanding production and development infrastructure to support growing demand for biologics and advanced therapies. For instance, in April 2026, REPROCELL announced a new GMP-compliant cell culture facility, strengthening its regenerative-medicine manufacturing capabilities.
- Growing Integration of Digital Bioprocessing: Market players are integrating automation, artificial intelligence (AI), process analytical technologies (PAT), advanced sensors and real-time monitoring into bioreactor platforms to improve process control, productivity and manufacturing efficiency. In April 2026, Cellcraft launched an AI operating system for bioreactors aimed at addressing process-control gaps in biomanufacturing.
- Regulatory Compliance and Process Control: Bioreactor operations used in regulated pharmaceutical manufacturing must support reproducible process control, equipment qualification, verification and validation, calibrated sensor performance, traceable data and current good manufacturing practice. U.S. Food and Drug Administration (FDA) expectations around controlled manufacturing systems reinforce the importance of data integrity, reliable automation and documented process performance.
- Sustainability and Lifecycle Economics: Single-use systems can reduce water, steam and cleaning-related utility requirements, but they increase dependence on disposable polymer consumables. Stainless steel systems require greater cleaning and maintenance infrastructure but offer long service life and reuse. Manufacturers are therefore evaluating total cost of ownership and environmental footprint rather than treating either platform as inherently more sustainable.
Pay Only for What You Need – The Best Way to Optimize
Market Segments
Based on the research, we have segmented the bioreactors market into type of bioreactor, type of bioprocesses, type of biologic, type of cell culture, scale of bioreactor and geographical regions.
- By Type of Bioreactor: Stainless Steel, Single-use, Glass
- By Type of Bioprocesses: Batch and Fed-batch, Continuous
- By Type of Biologic: Monoclonal Antibodies, Peptides, Vaccines, Cell and Gene Therapies, Biosimilars, Bispecific / Multispecific Antibodies, ADC's, mRNA, Other Biologics
- By Type of Cell Culture: Mammalian Cell Cultures, Microbial Cell Cultures, Insect Cell Cultures, Plant Cell Cultures, Other Cell Cultures
- By Scale of Bioreactor: Micro-scale Bioreactors, Lab-scale Bioreactors, Large-scale Bioreactors, Very Large-scale Bioreactors
- By Geographical Regions: North America, Europe, Asia-Pacific, Rest of the World
Market Segmentation Analysis
Which Type of Bioreactor Holds the Largest Market Share?
Stainless steel bioreactors currently capture the largest market share because they are durable, compatible with repeated cleaning and sterilization and well suited to large-scale, multi-batch commercial production.
Which Bioprocess Type Leads the Bioreactors Market?
Batch and fed-batch bioprocesses account for nearly 85% of the bioreactors market, reflecting their technical robustness and broad acceptance across commercial biomanufacturing facilities. Continuous bioprocessing is expected to grow at a comparatively faster CAGR through 2035, supported by its potential to improve productivity, reduce facility footprint, lower operating cost and enhance process consistency.
Which Type of Biologic Drives the Largest Share?
Monoclonal antibodies represent the leading biologic segment in 2026, supported by established commercial demand and extensive use of mammalian-cell bioreactor platforms. The mRNA segment is expected to grow comparatively faster as manufacturers expand production capabilities for mRNA-based vaccines and therapeutics and related upstream bioprocess requirements.
Which Bioreactor Scale Holds the Largest Market Share?
Very large-scale bioreactors account for more than 80% of the market by scale in 2026, supported by high-volume production requirements and economies of scale in commercial biopharmaceutical manufacturing. Large-scale bioreactors are expected to grow at a comparatively faster CAGR during the forecast period, supported by biomanufacturing capacity expansion and increasing use of flexible systems in the 500-5,000 L range for scale-up and pilot-to-commercial transitions.
Which Cell Culture Type Leads the Bioreactors Market?
Mammalian cell cultures capture the largest share of the bioreactors market because they are extensively used for commercial manufacture of monoclonal antibodies and other complex therapeutic proteins. Microbial cell cultures are expected to expand faster, supported by industrial fermentation applications involving bacteria and other microbial hosts for enzymes, insulin, plasmid DNA and high-yield recombinant products.
Market Regional Insights
Why Does Europe Lead the Bioreactors Market?
Europe is expected to remain the largest regional bioreactors market, capturing approximately 35% of the market during the forecast period, followed by North America. The region benefits from established biopharmaceutical manufacturing infrastructure, research and innovation capabilities, investment in advanced bioprocessing capacity and broad adoption of next-generation bioreactor technologies.
Why is Asia-Pacific the Fastest Growing Region?
Asia-Pacific is expected to register the fastest regional growth during the forecast period, supported by expanding biologics and biosimilars manufacturing capacity, increasing biopharmaceutical investment and strengthening biotechnology research activity across the region.
Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed
Key Players Profiled in the Bioreactors Market
Examples of key companies profiled in this market report include ABEC, Avantica Pharmaceuticals, Bilfinger Life Science, Bioengineering, Broadley-James, Chemglass Life Sciences, Cytiva (a Danaher company), De Dietrich Process Systems, Distek, Ekato, Eppendorf, GEA, Getinge, IKA, Infors HT, INOXPA, Kuhner Shaker, Labtron, Merck Millipore, Morimatsu LifeSciences, Pall Corporation (a Danaher company), Parr Instrument Company, PBS Biotech, PerfuseCell, Pierre Guerin, REPROCELL, Sartorius, Solaris Biotech, Solida Biotech, Thermo Fisher Scientific. The complete report includes an expanded database of close to 55 bioreactor companies worldwide. Company names and trademarks are referenced solely for market-analysis and competitive-benchmarking purposes; inclusion does not imply affiliation, endorsement or sponsorship by Roots Analysis.
Report Deliverables and Customization
Alongside the core market report, clients receive complimentary Excel data packs covering the bioreactors market landscape, product competitiveness, partnerships and collaborations, market sizing and opportunity analysis and selected manufacturer benchmarking. A complimentary PowerPoint presentation summarizing the report is also included, and 15% free customization is available on request. The report is designed to support biopharmaceutical and biotechnology companies, process-development and manufacturing teams, procurement and technical-operations functions, quality and regulatory professionals, CMOs / CDMOs, investors and competitive-intelligence teams evaluating bioreactor technologies, vendors, capacity strategies and regional opportunities.
Report Authorship
This report was authored by Simriti Gupta, part of Roots Analysis healthcare and pharma research practice. Her work on this study focuses on bioreactor technologies, bioprocessing trends, manufacturer benchmarking, manufacturing-capacity expansion and adoption across pharmaceutical and biotechnology companies. Findings are based on proprietary databases, secondary research, expert discussions and internal review prior to publication.
Independence and Non-Affiliation
Roots Analysis is an independent market research and consulting firm. This report is not affiliated with, endorsed by, sponsored by or produced on behalf of any bioreactor manufacturer, pharmaceutical company, biotechnology company, CMO, CDMO or other organization named or profiled within the study.
The findings are developed independently through secondary research, proprietary databases and primary discussions with industry stakeholders. Company, product and regulatory references are included solely for factual, market-analysis and competitive-intelligence purposes.
